Wegovy Now Available Through Hims & Hers at $599 Monthly Bundle
Novo Nordisk and Hims & Hers have announced a groundbreaking collaboration to make obesity care more accessible and affordable in the United States. The partnership's first initiative introduces Wegovy through the Hims & Hers platform, bundled with comprehensive healthcare services.
The offering, priced at $599 per month, includes:
- All dose strengths of Wegovy
- 24/7 care access
- Ongoing clinical support
- Nutrition guidance
- Hims & Hers membership
Patients can now access NovoCare Pharmacy directly through the Hims & Hers platform. This collaboration combines Novo Nordisk's innovative treatments with Hims & Hers' scalable healthcare delivery system. The partnership aims to improve long-term outcomes for people living with obesity while maintaining affordability. The platform will continue offering additional weight loss solutions, including oral medications, protein supplements, nutrition kits, and clinically-backed care plans.
Novo Nordisk e Hims & Hers hanno annunciato una collaborazione innovativa per rendere l'assistenza all'obesità più accessibile e conveniente negli Stati Uniti. La prima iniziativa della partnership introduce Wegovy attraverso la piattaforma Hims & Hers, integrato con servizi sanitari completi.
L'offerta, al prezzo di 599 dollari al mese, comprende:
- Tutte le dosi di Wegovy
- Accesso alle cure 24/7
- Supporto clinico continuo
- Consulenza nutrizionale
- Iscrizione a Hims & Hers
I pazienti possono ora accedere direttamente a NovoCare Pharmacy tramite la piattaforma Hims & Hers. Questa collaborazione unisce i trattamenti innovativi di Novo Nordisk con il sistema di erogazione sanitaria scalabile di Hims & Hers. L'obiettivo è migliorare i risultati a lungo termine per le persone con obesità, mantenendo l'accessibilità economica. La piattaforma continuerà a offrire ulteriori soluzioni per la perdita di peso, inclusi farmaci orali, integratori proteici, kit nutrizionali e piani di cura supportati clinicamente.
Novo Nordisk y Hims & Hers han anunciado una colaboración innovadora para hacer que el cuidado de la obesidad sea más accesible y asequible en Estados Unidos. La primera iniciativa de esta alianza presenta Wegovy a través de la plataforma de Hims & Hers, junto con servicios integrales de atención médica.
La oferta, con un precio de 599 dólares al mes, incluye:
- Todas las dosis de Wegovy
- Acceso a atención 24/7
- Soporte clínico continuo
- Asesoramiento nutricional
- Membresía de Hims & Hers
Los pacientes ahora pueden acceder directamente a NovoCare Pharmacy a través de la plataforma de Hims & Hers. Esta colaboración combina los tratamientos innovadores de Novo Nordisk con el sistema escalable de atención médica de Hims & Hers. El objetivo es mejorar los resultados a largo plazo para las personas con obesidad, manteniendo la asequibilidad. La plataforma seguirá ofreciendo soluciones adicionales para la pérdida de peso, incluyendo medicamentos orales, suplementos de proteínas, kits de nutrición y planes de cuidado clínicamente respaldados.
노보 노디스크와 Hims & Hers가 미국 내 비만 치료를 보다 접근하기 쉽고 저렴하게 만들기 위한 획기적인 협력을 발표했습니다. 이번 파트너십의 첫 번째 이니셔티브로 Hims & Hers 플랫폼을 통해 웨고비(Wegovy)가 종합 의료 서비스와 함께 제공됩니다.
월 599달러에 제공되는 이 패키지에는 다음이 포함됩니다:
- 웨고비 모든 용량
- 24시간 연중무휴 케어 접근
- 지속적인 임상 지원
- 영양 상담
- Hims & Hers 멤버십
환자들은 이제 Hims & Hers 플랫폼을 통해 직접 NovoCare Pharmacy에 접근할 수 있습니다. 이번 협력은 노보 노디스크의 혁신적인 치료법과 Hims & Hers의 확장 가능한 의료 제공 시스템을 결합한 것입니다. 파트너십은 비만 환자의 장기적인 치료 성과를 개선하면서도 경제적 부담을 낮추는 것을 목표로 합니다. 또한 플랫폼은 경구용 약물, 단백질 보충제, 영양 키트, 임상적으로 검증된 치료 계획 등 추가 체중 감량 솔루션도 계속 제공할 예정입니다.
Novo Nordisk et Hims & Hers ont annoncé une collaboration révolutionnaire visant à rendre les soins contre l'obésité plus accessibles et abordables aux États-Unis. La première initiative de ce partenariat introduit Wegovy via la plateforme Hims & Hers, accompagné de services de santé complets.
Cette offre, au prix de 599 dollars par mois, comprend :
- Toutes les doses de Wegovy
- Accès aux soins 24h/24 et 7j/7
- Support clinique continu
- Conseils nutritionnels
- Adhésion à Hims & Hers
Les patients peuvent désormais accéder directement à la pharmacie NovoCare via la plateforme Hims & Hers. Cette collaboration combine les traitements innovants de Novo Nordisk avec le système de prestation de soins évolutif de Hims & Hers. Le partenariat vise à améliorer les résultats à long terme pour les personnes vivant avec l'obésité tout en maintenant l'accessibilité financière. La plateforme continuera à proposer d'autres solutions de perte de poids, y compris des médicaments oraux, des compléments protéinés, des kits nutritionnels et des plans de soins cliniquement validés.
Novo Nordisk und Hims & Hers haben eine bahnbrechende Zusammenarbeit angekündigt, um die Versorgung von Adipositas in den USA zugänglicher und erschwinglicher zu machen. Die erste Initiative der Partnerschaft führt Wegovy über die Hims & Hers-Plattform ein, kombiniert mit umfassenden Gesundheitsdienstleistungen.
Das Angebot kostet 599 US-Dollar pro Monat und beinhaltet:
- Alle Dosierungsstärken von Wegovy
- Rund-um-die-Uhr-Zugang zur Versorgung
- Kontinuierliche klinische Unterstützung
- Ernährungsberatung
- Mitgliedschaft bei Hims & Hers
Patienten können nun direkt über die Hims & Hers-Plattform auf die NovoCare Pharmacy zugreifen. Diese Zusammenarbeit vereint die innovativen Behandlungen von Novo Nordisk mit dem skalierbaren Gesundheitssystem von Hims & Hers. Ziel der Partnerschaft ist es, langfristige Ergebnisse für Menschen mit Adipositas zu verbessern und gleichzeitig die Erschwinglichkeit zu gewährleisten. Die Plattform wird weiterhin zusätzliche Gewichtsverlustlösungen anbieten, darunter orale Medikamente, Proteinergänzungen, Ernährungskits und klinisch fundierte Behandlungspläne.
- Strategic partnership with Novo Nordisk provides access to high-demand Wegovy medication
- New bundled offering at $599/month creates additional revenue stream
- Direct integration with NovoCare Pharmacy streamlines distribution
- Expansion of weight loss solutions portfolio strengthens market position
- Long-term collaboration potential for future product offerings
- High monthly cost of $599 may limit market penetration
- Dependence on single supplier (Novo Nordisk) for key product
- No exclusivity mentioned in the partnership agreement
- Competitive pressure in increasingly crowded weight loss market
Insights
Partnership with Novo Nordisk adds Wegovy to Hims & Hers platform, creating premium bundled weight management offering at $599 monthly.
The newly announced partnership between Hims & Hers and Novo Nordisk represents a strategic expansion in the competitive weight management market. This collaboration enables direct access to Wegovy®, Novo Nordisk's FDA-approved weight loss medication, through the Hims & Hers telehealth platform at a
What makes this deal particularly significant is its integrated approach to obesity care. Rather than simply offering medication access, Hims & Hers is creating a holistic treatment model that combines pharmaceutical intervention with ongoing support services – addressing a key need in effective long-term weight management.
The press release explicitly positions this as the "first step in a long-term collaboration roadmap" between the companies, suggesting broader strategic intentions beyond this initial offering. By securing direct access to one of the most sought-after weight loss medications and creating a streamlined patient experience through NovoCare® Pharmacy integration, Hims & Hers is strengthening its position in the rapidly evolving telehealth weight management sector.
The immediate availability of this offering ("available this week") indicates rapid implementation capabilities, while the company's confirmation that it will maintain its existing portfolio of weight management solutions provides service diversification across multiple price points and treatment approaches.
Hims & Hers secures access to high-demand Wegovy treatment, creating integrated care model with potential for expanded pharmaceutical partnerships.
This partnership represents a significant development in consumer access to GLP-1 medications for weight management. By securing direct distribution of Wegovy® (semaglutide), Hims & Hers gains access to one of the most clinically effective and in-demand obesity treatments currently available. The press release specifies the offering includes "all dose strengths of Wegovy®" which is medically important as proper dose titration is critical for patient tolerability and outcomes.
The
Particularly noteworthy is the emphasis on a "long-term collaboration roadmap" between the companies, with explicit mention of combining "Novo Nordisk's innovative treatments with Hims & Hers' ability to scale access to quality care." This language suggests strategic alignment between the companies extends beyond this single medication.
The bundled model combining pharmaceutical treatment with support services aligns with clinical best practices for obesity management, where comprehensive approaches typically yield better outcomes than medication alone. The press release's focus on "improving long-term outcomes for more people, more affordably" indicates a sustained commitment to addressing obesity as a chronic condition rather than offering a quick-fix solution.
Hims & Hers Partners with Novo Nordisk to Offer Wegovy® Treatment on Its Platform
Hims & Hers Health, Inc. (NYSE: HIMS) and Novo Nordisk announced on April 29, 2025, a long-term collaboration aimed at making obesity care and treatments more accessible and affordable for millions of Americans. The partnership begins with the immediate availability of Novo Nordisk's FDA-approved weight loss medication Wegovy® through the Hims & Hers platform.
According to the announcement, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering that includes all dose strengths of Wegovy® alongside a Hims & Hers membership. The comprehensive package provides access to 24/7 care, ongoing clinical support, and nutrition guidance at a unified price starting at
The companies stated that this initial offering is available this week on the Hims & Hers platform. The collaboration represents the first step in what the companies describe as a longer-term partnership roadmap.
Strategic Vision
Andrew Dudum, CEO and founder of Hims & Hers, emphasized the significance of the partnership in the press release: "We're excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications. We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future."
The partnership aligns with both companies' goals of expanding access to obesity treatment. Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc., noted: "We are pleased that Hims & Hers is making this offering available this week to people living with obesity. Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers' ability to deliver access to quality care at scale."
Enhanced Weight Management Offerings
The press release indicated that this new offering builds upon Hims & Hers' existing suite of weight loss solutions. The company said it will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans on its platform.
According to the announcement, the bundled offering provides self-pay patients access to all dose strengths of Wegovy® in a high-quality pen format, giving patients more options to start and sustain their health journey based on their needs, goals, and eligibility.
The companies emphasized that their developing roadmap aims to improve long-term outcomes for more people living with chronic disease, potentially expanding beyond obesity care in the future. Both organizations expressed their shared commitment to delivering consumer-centered healthcare solutions.
This article is based solely on information provided in Hims & Hers Health, Inc.'s press release dated April 29, 2025. The content is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Stock Titan and its writers make no representations as to the accuracy, completeness, or timeliness of the information. Investors should conduct their own due diligence before making any investment decisions.
Source: Hims & Hers
FAQ
How much does Wegovy cost on Hims & Hers (NYSE: HIMS) platform in 2025?
What is included in the Novo Nordisk and Hims & Hers (HIMS) obesity care partnership?
Where can I buy Wegovy through Hims & Hers stock (HIMS) platform?
Will Hims & Hers (HIMS) stock benefit from the Novo Nordisk Wegovy partnership?
What weight loss medications does Hims & Hers (HIMS) offer in 2025?
